Barclays
GLUE icon

Barclays’s Monte Rosa Therapeutics GLUE Stock Holding History

Barclays’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$834K Buy
34,467
+23,114
+204% +$437K ﹤0.01% 2897
2026
Q1 		$187K Sell
11,353
-124,631
-92% -$2.38M ﹤0.01% 3726
2025
Q4 		$2.13M Buy
135,984
+63,029
+86% +$849K ﹤0.01% 2881
2025
Q3 		$541K Sell
72,955
-12,757
-15% -$67.6K ﹤0.01% 3764
2025
Q2 		$387K Buy
85,712
+39,502
+85% +$176K ﹤0.01% 3904
2025
Q1 		$214K Sell
46,210
-24,531
-35% -$150K ﹤0.01% 4002
2024
Q4 		$491K Buy
70,741
+16,233
+30% +$122K ﹤0.01% 3837
2024
Q3 		$289K Buy
54,508
+43,499
+395% +$220K ﹤0.01% 4109
2024
Q2 		$41.2K Sell
11,009
-10,739
-49% -$54.8K ﹤0.01% 4284
2024
Q1 		$153K Sell
21,748
-39,520
-65% -$234K ﹤0.01% 4245
2023
Q4 		$346K Buy
61,268
+48,097
+365% +$189K ﹤0.01% 4117
2023
Q3 		$63.1K Sell
13,171
-464
-3% -$2.99K ﹤0.01% 3768
2023
Q2 		$93.4K Sell
13,635
-1,534
-10% -$9.92K ﹤0.01% 3588
2023
Q1 		$118K Buy
15,169
+7,181
+90% +$49.9K ﹤0.01% 4091
2022
Q4 		$60.8K Buy
7,988
+6,772
+557% +$56.4K ﹤0.01% 4469
2022
Q3 		$10K Sell
1,216
-224
-16% -$2.06K ﹤0.01% 4298
2022
Q2 		$14K Sell
1,440
-7,668
-84% -$77K ﹤0.01% 4517
2022
Q1 		$128K Buy
+9,108
New +$126K ﹤0.01% 3676

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's GLUE Position: Q2 2026 in Review

Barclays increased its Monte Rosa Therapeutics (GLUE) stake by 204% in Q2 2026, buying an estimated $437K and bringing the position to 34,467 shares worth $834K. The position accounts for ﹤0.01% of the portfolio, ranked #2897.

Barclays first reported a position in GLUE in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.13M in Q4 2025. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Barclays held 34,467 shares of Monte Rosa Therapeutics worth $834K as of Q2 2026.
  • Barclays bought 23,114 Monte Rosa Therapeutics shares in Q2 2026, an estimated $437K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2897 holding.
  • Barclays first reported a position in Monte Rosa Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Monte Rosa Therapeutics position peaked at $2.13M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.